Summary of findings for the main comparison. GTN versus Placebo for anal fissure.
| GTN versus Placebo for anal fissure | ||||||
| Patient or population: patients with anal fissure Settings: Intervention: GTN versus Placebo | ||||||
| Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | Comments | |
| Assumed risk | Corresponding risk | |||||
| Control | GTN versus Placebo | |||||
| NON ‐ Healing of fissure (persistence or recurrence) Follow‐up: median 2 months | Study population | OR 0.35 (0.19 to 0.65) | 1315 (18 studies) | ⊕⊕⊝⊝ low1,2 | ||
| 645 per 1000 | 388 per 1000 (256 to 541) | |||||
| Moderate | ||||||
| 674 per 1000 | 420 per 1000 (282 to 573) | |||||
| *The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI). CI: Confidence interval; OR: Odds ratio; | ||||||
| GRADE Working Group grades of evidence High quality: Further research is very unlikely to change our confidence in the estimate of effect. Moderate quality: Further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate. Low quality: Further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate. Very low quality: We are very uncertain about the estimate. | ||||||
1 RANDOMIZATION SELDOM SPECIFIED AND FOLLOW UP WAY TOO SHORT 2 VARIABLE RESULTS